These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 30662590)

  • 41. Fecal microbiota transplantation: in perspective.
    Gupta S; Allen-Vercoe E; Petrof EO
    Therap Adv Gastroenterol; 2016 Mar; 9(2):229-39. PubMed ID: 26929784
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Therapeutic Potential of the Gut Microbiota in the Prevention and Treatment of Sepsis.
    Haak BW; Prescott HC; Wiersinga WJ
    Front Immunol; 2018; 9():2042. PubMed ID: 30250472
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Modulating Composition and Metabolic Activity of the Gut Microbiota in IBD Patients.
    Matijašić M; Meštrović T; Perić M; Čipčić Paljetak H; Panek M; Vranešić Bender D; Ljubas Kelečić D; Krznarić Ž; Verbanac D
    Int J Mol Sci; 2016 Apr; 17(4):. PubMed ID: 27104515
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies.
    Hudson LE; Anderson SE; Corbett AH; Lamb TJ
    Clin Microbiol Rev; 2017 Jan; 30(1):191-231. PubMed ID: 27856521
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Gut Microbiota and Chronic Constipation: A Review and Update.
    Ohkusa T; Koido S; Nishikawa Y; Sato N
    Front Med (Lausanne); 2019; 6():19. PubMed ID: 30809523
    [No Abstract]   [Full Text] [Related]  

  • 46. Role of the microbiome, probiotics, and 'dysbiosis therapy' in critical illness.
    Wischmeyer PE; McDonald D; Knight R
    Curr Opin Crit Care; 2016 Aug; 22(4):347-53. PubMed ID: 27327243
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Modulating the microbiota in inflammatory bowel diseases: prebiotics, probiotics or faecal transplantation?
    Verbeke KA; Boesmans L; Boets E
    Proc Nutr Soc; 2014 Nov; 73(4):490-7. PubMed ID: 24969143
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gut Microbiota as a Therapeutic Target for Metabolic Disorders.
    Okubo H; Nakatsu Y; Kushiyama A; Yamamotoya T; Matsunaga Y; Inoue MK; Fujishiro M; Sakoda H; Ohno H; Yoneda M; Ono H; Asano T
    Curr Med Chem; 2018; 25(9):984-1001. PubMed ID: 28990516
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Altered Gut Microbiota in HIV Infection: Future Perspective of Fecal Microbiota Transplantation Therapy.
    Kang Y; Cai Y
    AIDS Res Hum Retroviruses; 2019 Mar; 35(3):229-235. PubMed ID: 29877092
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Fecal Microbiota Transplantation in Inflammatory Bowel Disease: A Primer for Internists.
    Syal G; Kashani A; Shih DQ
    Am J Med; 2018 Sep; 131(9):1017-1024. PubMed ID: 29605414
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gut microbiota in the pathogenesis of inflammatory bowel disease.
    Nishida A; Inoue R; Inatomi O; Bamba S; Naito Y; Andoh A
    Clin J Gastroenterol; 2018 Feb; 11(1):1-10. PubMed ID: 29285689
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Is fecal microbiota transplantation (FMT) an effective treatment for patients with functional gastrointestinal disorders (FGID)?
    Pinn DM; Aroniadis OC; Brandt LJ
    Neurogastroenterol Motil; 2015 Jan; 27(1):19-29. PubMed ID: 25424663
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Challenges in fecal donor selection and screening for fecal microbiota transplantation: A review.
    Woodworth MH; Carpentieri C; Sitchenko KL; Kraft CS
    Gut Microbes; 2017 May; 8(3):225-237. PubMed ID: 28129018
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Successful therapy of Clostridium difficile infection with fecal microbiota transplantation.
    Konturek PC; Koziel J; Dieterich W; Haziri D; Wirtz S; Glowczyk I; Konturek K; Neurath MF; Zopf Y
    J Physiol Pharmacol; 2016 Dec; 67(6):859-866. PubMed ID: 28195066
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fecal microbiota transplantation: a new old kid on the block for the management of gut microbiota-related disease.
    Cammarota G; Ianiro G; Bibbò S; Gasbarrini A
    J Clin Gastroenterol; 2014; 48 Suppl 1():S80-4. PubMed ID: 25291136
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Gut microbiota and obesity: An opportunity to alter obesity through faecal microbiota transplant (FMT).
    Lee P; Yacyshyn BR; Yacyshyn MB
    Diabetes Obes Metab; 2019 Mar; 21(3):479-490. PubMed ID: 30328245
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prebiotic effects: metabolic and health benefits.
    Roberfroid M; Gibson GR; Hoyles L; McCartney AL; Rastall R; Rowland I; Wolvers D; Watzl B; Szajewska H; Stahl B; Guarner F; Respondek F; Whelan K; Coxam V; Davicco MJ; Léotoing L; Wittrant Y; Delzenne NM; Cani PD; Neyrinck AM; Meheust A
    Br J Nutr; 2010 Aug; 104 Suppl 2():S1-63. PubMed ID: 20920376
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Fecal microbiota transplantation for gastrointestinal disorders.
    Malikowski T; Khanna S; Pardi DS
    Curr Opin Gastroenterol; 2017 Jan; 33(1):8-13. PubMed ID: 28134687
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical Efficacy and Microbiome Changes Following Fecal Microbiota Transplantation in Children With Recurrent Clostridium Difficile Infection.
    Li X; Gao X; Hu H; Xiao Y; Li D; Yu G; Yu D; Zhang T; Wang Y
    Front Microbiol; 2018; 9():2622. PubMed ID: 30450088
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pancreatic Diseases and Microbiota: A Literature Review and Future Perspectives.
    Gesualdo M; Rizzi F; Bonetto S; Rizza S; Cravero F; Saracco GM; De Angelis CG
    J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33139601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.